US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

13.68

+0.19001.41%

Volume:1.19M

Turnover:16.74M

Market Cap:428.05M

PE:-6.49

High:14.97

Open:13.01

Low:12.90

Close:13.49

52wk High:50.40

52wk Low:11.48

Shares:31.29M

Float Shares:15.69M

Volume Ratio:1.59

T/O Rate:7.58%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.1087

EPS(LYR):-2.3387

ROE:-28.78%

ROA:-19.52%

PB:2.21

PE(LYR):-5.85

Loading ...

Overview Company News Filings

Press Release: Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer

Galera Therapeutics Updates Preferred Stock Conversion Provisions

Atossa Therapeutics Regains Nasdaq Compliance, Avoids Delisting Risk

Press Release: Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026

Shield Therapeutics Iron Deficiency Drug Approved for Children

Crispr Therapeutics price target raised to $33 from $32 at Morgan Stanley

Outlook Therapeutics reports adjusted Q1 EPS (22c), consensus (17c)

Outlook Therapeutics Q1 Adj. EPS $(0.22) Misses $(0.18) Estimate, Sales $(1.208M) Miss $5.025M Estimate

Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board

Autolus Therapeutics Initiated at Buy by HC Wainwright & Co.

Autolus Therapeutics initiated with a Buy at H.C. Wainwright

Dianthus Therapeutics: Best-in-Class Complement Inhibitor Potential and Multiple 2026 Catalysts Support Buy Rating

Assessing CARsgen Therapeutics Holdings’ Valuation After New CAR T-Cell Manufacturing Cooperation News

Simply Wall St.

Crispr Therapeutics price target lowered to $67 from $69 at JPMorgan

Dianthus Therapeutics: Multi-Indication Potential for Claseprubart Underpins Buy Rating Ahead of Key Phase II Readouts

Crispr Therapeutics price target raised to $76 from $74 at Chardan

High-Risk Warning: Analyst Flags Significant Uncertainties for Vistagen Therapeutics Investors

Vistagen Therapeutics Balances Progress and Uncertainty

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LENZ/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LENZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":13.68,"timestamp":1772485200000,"preClose":13.49,"halted":0,"volume":1189548,"delay":0,"changeRate":0.014084507042253483,"floatShares":15692500,"shares":31289969,"eps":-2.10871,"marketStatus":"Pre-Mkt","change":0.19,"latestTime":"03-03 06:33:59 EST","open":13.01,"high":14.97,"low":12.9001,"amount":16739414.61984,"amplitude":0.15344,"askPrice":16.27,"askSize":200,"bidPrice":12,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-2.10871,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1772548200000},"marketStatusCode":1,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":13.68,"postHourTrading":{"tag":"盘后","latestPrice":13.75,"preClose":13.68,"latestTime":"19:20 EST","volume":32741,"amount":453311.12,"timestamp":1772497214907,"change":0.07,"changeRate":0.005117,"amplitude":0.085892},"volumeRatio":1.5868910184600635,"impliedVol":1.3041,"impliedVolPercentile":0.9866},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","floatShares":15692500,"roa":"-19.52%","roe":"-28.78%","lyrEps":-2.338654,"volumeRatio":1.5868910184600635,"shares":31289969,"dividePrice":0,"high":14.97,"amplitude":0.15344,"preClose":13.49,"low":12.9001,"week52Low":11.48,"pbRate":"2.21","psRate":"24.46","week52High":50.4,"institutionHeld":0,"latestPrice":13.68,"committee":-0.904762,"eps":-2.10871,"divideRate":0,"volume":1189548,"delay":0,"ttmEps":-2.10871,"open":13.01,"prevYearClose":16,"prevWeekClose":13.49,"prevMonthClose":13.49,"prevQuarterClose":16,"fiveDayClose":11.89,"twentyDayClose":15.82,"sixtyDayClose":27.31},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LENZ\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-01-07","symbol":"LENZ","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1767762000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-11-05","symbol":"LENZ","fiscalQuarterEnding":"2025/09","expectedEps":-0.67,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762318800000,"reportTimeType":"pre","actualEps":-0.59},{"market":"US","date":"2025-07-30","symbol":"LENZ","fiscalQuarterEnding":"2025/06","expectedEps":-0.58,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1753848000000,"reportTimeType":"pre","actualEps":-0.53},{"market":"US","date":"2024-05-08","symbol":"LENZ","fiscalQuarterEnding":"2024/03","expectedEps":-0.84,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715140800000,"reportTimeType":"pre","actualEps":-3.53},{"market":"US","date":"2024-03-22","symbol":"LENZ","defaultRemindTime":1711114200000,"type":"split","dateTimestamp":1711080000000,"forFactor":7,"toFactor":1,"ratio":7}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LENZ\",market:\"US\",,,undefined,":[{"executeDate":"2024-03-22","recordDate":"2024-03-18","paymentDate":"2024-03-21","value":1.03,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LENZ\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5714,"buy":0.4286,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5714,"analysts":7,"updateTime":1742360400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LENZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LENZ","date":"2026-03-02","current":-6.487379,"percent":0.857759,"low":-26.69966,"twenty":-17.078714,"median":-11.387664,"eighty":-8.080293,"high":-5.069183,"avg":-12.734793,"sd":5.134332,"marketCap":422101681},"quantilePoints":[{"date":"2024-03-28","current":-7.959158,"twenty":-7.219077,"median":-6.108955,"eighty":-6.016992,"marketCap":556886354},{"date":"2024-04-05","current":-7.492045,"twenty":-7.873034,"median":-7.667213,"eighty":-6.662191,"marketCap":524203432},{"date":"2024-04-12","current":-7.929963,"twenty":-7.855517,"median":-7.667213,"eighty":-7.432197,"marketCap":554843672},{"date":"2024-04-19","current":-6.382653,"twenty":-7.855517,"median":-7.488396,"eighty":-6.783348,"marketCap":446581492},{"date":"2024-04-26","current":-5.638193,"twenty":-7.716113,"median":-7.451903,"eighty":-5.889996,"marketCap":394493084},{"date":"2024-05-03","current":-5.988527,"twenty":-7.671592,"median":-6.864363,"eighty":-5.803142,"marketCap":419005276},{"date":"2024-05-10","current":-5.317808,"twenty":-7.667213,"median":-6.108955,"eighty":-5.803142,"marketCap":393230653},{"date":"2024-05-17","current":-5.708011,"twenty":-7.597146,"median":-6.0013,"eighty":-5.749862,"marketCap":422084590},{"date":"2024-05-24","current":-5.428308,"twenty":-7.489126,"median":-6.006774,"eighty":-5.719496,"marketCap":401401679},{"date":"2024-05-31","current":-5.355793,"twenty":-7.479638,"median":-5.988527,"eighty":-5.522773,"marketCap":396039443},{"date":"2024-06-07","current":-5.193496,"twenty":-7.457742,"median":-5.904593,"eighty":-5.428999,"marketCap":384038248},{"date":"2024-06-14","current":-6.433167,"twenty":-7.451903,"median":-5.930138,"eighty":-5.428308,"marketCap":475706952},{"date":"2024-06-21","current":-6.236339,"twenty":-7.425628,"median":-5.992177,"eighty":-5.43107,"marketCap":461152311},{"date":"2024-06-28","current":-6.150011,"twenty":-7.389135,"median":-6.0013,"eighty":-5.439358,"marketCap":454768696},{"date":"2024-07-05","current":-6.098214,"twenty":-7.269437,"median":-6.014073,"eighty":-5.469746,"marketCap":450938528},{"date":"2024-07-12","current":-6.771573,"twenty":-6.771573,"median":-6.098214,"eighty":-5.493918,"marketCap":500730721},{"date":"2024-07-15","current":-7.261916,"twenty":-7.163847,"median":-6.103393,"eighty":-5.509112,"marketCap":536989651},{"date":"2024-08-02","current":-8.498134,"twenty":-7.266429,"median":-6.108573,"eighty":-5.524305,"marketCap":628403011},{"date":"2024-08-09","current":-8.328931,"twenty":-7.474529,"median":-6.146558,"eighty":-5.597209,"marketCap":615891126},{"date":"2024-08-16","current":-8.944708,"twenty":-7.671592,"median":-6.236339,"eighty":-5.641258,"marketCap":621424629},{"date":"2024-08-23","current":-8.79431,"twenty":-7.94748,"median":-6.352018,"eighty":-5.670717,"marketCap":610975896},{"date":"2024-08-30","current":-8.746816,"twenty":-8.006409,"median":-6.382653,"eighty":-5.719496,"marketCap":607676296},{"date":"2024-09-06","current":-9.451311,"twenty":-8.199004,"median":-6.419354,"eighty":-5.743293,"marketCap":656620360},{"date":"2024-09-13","current":-8.17293,"twenty":-8.352945,"median":-6.434893,"eighty":-5.773217,"marketCap":567806132},{"date":"2024-09-20","current":-8.7389,"twenty":-8.507104,"median":-6.459289,"eighty":-5.788545,"marketCap":607126363},{"date":"2024-09-27","current":-8.806184,"twenty":-8.638371,"median":-6.616182,"eighty":-5.792924,"marketCap":611800796},{"date":"2024-10-04","current":-8.897214,"twenty":-8.745233,"median":-7.269437,"eighty":-5.800953,"marketCap":618125029},{"date":"2024-10-11","current":-9.340491,"twenty":-8.850511,"median":-7.455552,"eighty":-5.81701,"marketCap":648921294},{"date":"2024-10-18","current":-10.417023,"twenty":-8.905129,"median":-7.492045,"eighty":-5.857882,"marketCap":723712222},{"date":"2024-10-25","current":-9.902504,"twenty":-9.0017,"median":-7.670862,"eighty":-5.904593,"marketCap":687966558},{"date":"2024-10-31","current":-10.939457,"twenty":-9.257377,"median":-7.718702,"eighty":-5.904593,"marketCap":760007820},{"date":"2024-11-08","current":-14.709443,"twenty":-9.419648,"median":-7.959158,"eighty":-5.955683,"marketCap":894466512},{"date":"2024-11-15","current":-15.344855,"twenty":-9.514636,"median":-8.00261,"eighty":-5.970448,"marketCap":933105265},{"date":"2024-11-22","current":-15.521232,"twenty":-9.76398,"median":-8.132103,"eighty":-5.988527,"marketCap":943830613},{"date":"2024-11-29","current":-16.100113,"twenty":-9.924668,"median":-8.17293,"eighty":-5.994366,"marketCap":979031755},{"date":"2024-12-06","current":-16.33076,"twenty":-10.388526,"median":-8.285117,"eighty":-6.004584,"marketCap":993057210},{"date":"2024-12-13","current":-13.920266,"twenty":-10.815972,"median":-8.351032,"eighty":-6.018452,"marketCap":846477455},{"date":"2024-12-20","current":-13.694141,"twenty":-11.182468,"median":-8.50374,"eighty":-6.082845,"marketCap":832727009},{"date":"2024-12-27","current":-14.476534,"twenty":-12.093039,"median":-8.531114,"eighty":-6.098214,"marketCap":880303552},{"date":"2025-01-03","current":-12.794163,"twenty":-13.449021,"median":-8.618187,"eighty":-6.102358,"marketCap":778000234},{"date":"2025-01-10","current":-11.912274,"twenty":-13.190334,"median":-8.707238,"eighty":-6.108649,"marketCap":724373495},{"date":"2025-01-17","current":-10.130408,"twenty":-13.019383,"median":-8.746816,"eighty":-6.115785,"marketCap":616019980},{"date":"2025-01-24","current":-11.197719,"twenty":-12.871045,"median":-8.79431,"eighty":-6.143105,"marketCap":680922085},{"date":"2025-01-31","current":-11.523339,"twenty":-12.794163,"median":-8.877425,"eighty":-6.150011,"marketCap":700722728},{"date":"2025-02-07","current":-12.070562,"twenty":-12.328345,"median":-8.905129,"eighty":-6.232886,"marketCap":733998807},{"date":"2025-02-14","current":-11.432889,"twenty":-12.292165,"median":-8.964497,"eighty":-6.236339,"marketCap":695222549},{"date":"2025-02-21","current":-11.279124,"twenty":-12.151063,"median":-8.998138,"eighty":-6.308164,"marketCap":685872246},{"date":"2025-02-28","current":-9.62841,"twenty":-12.079607,"median":-9.059485,"eighty":-6.342695,"marketCap":585493990},{"date":"2025-03-07","current":-10.297741,"twenty":-11.943932,"median":-9.320702,"eighty":-6.355126,"marketCap":626195310},{"date":"2025-03-14","current":-11.193196,"twenty":-11.879712,"median":-9.419648,"eighty":-6.365485,"marketCap":680647077},{"date":"2025-03-21","current":-14.554795,"twenty":-11.943932,"median":-9.482973,"eighty":-6.379634,"marketCap":724377586},{"date":"2025-03-28","current":-14.68208,"twenty":-12.421509,"median":-9.574004,"eighty":-6.398202,"marketCap":730712447},{"date":"2025-04-04","current":-12.728528,"twenty":-13.089934,"median":-9.668992,"eighty":-6.415901,"marketCap":633486102},{"date":"2025-04-11","current":-10.2603,"twenty":-12.90813,"median":-9.741473,"eighty":-6.42488,"marketCap":510644883},{"date":"2025-04-17","current":-12.761733,"twenty":-12.945214,"median":-9.779811,"eighty":-6.430405,"marketCap":635138674},{"date":"2025-04-25","current":-15.833323,"twenty":-13.271407,"median":-9.84549,"eighty":-6.435239,"marketCap":788008663},{"date":"2025-05-02","current":-15.982746,"twenty":-13.932929,"median":-9.940463,"eighty":-6.440764,"marketCap":795445305},{"date":"2025-05-09","current":-15.25222,"twenty":-14.136351,"median":-10.102399,"eighty":-6.452984,"marketCap":728141003},{"date":"2025-05-16","current":-16.118891,"twenty":-14.245886,"median":-10.138549,"eighty":-6.460191,"marketCap":769515850},{"date":"2025-05-23","current":-16.637714,"twenty":-14.356129,"median":-10.19625,"eighty":-6.460792,"marketCap":794284465},{"date":"2025-05-30","current":-17.410053,"twenty":-14.523491,"median":-10.236057,"eighty":-6.585104,"marketCap":831155927},{"date":"2025-06-06","current":-17.864023,"twenty":-14.65894,"median":-10.342966,"eighty":-6.96771,"marketCap":852828466},{"date":"2025-06-13","current":-17.439532,"twenty":-14.747436,"median":-10.384797,"eighty":-7.264924,"marketCap":832563235},{"date":"2025-06-20","current":-17.704839,"twenty":-14.88454,"median":-10.454615,"eighty":-7.299361,"marketCap":845229004},{"date":"2025-06-27","current":-17.752005,"twenty":-15.005667,"median":-10.623361,"eighty":-7.425628,"marketCap":847480696},{"date":"2025-07-03","current":-19.178768,"twenty":-15.33581,"median":-10.694071,"eighty":-7.451903,"marketCap":915594389},{"date":"2025-07-11","current":-20.198727,"twenty":-15.529319,"median":-10.766979,"eighty":-7.459202,"marketCap":964287236},{"date":"2025-07-18","current":-20.381494,"twenty":-15.833323,"median":-10.791578,"eighty":-7.484747,"marketCap":973012543},{"date":"2025-07-25","current":-19.691695,"twenty":-16.100113,"median":-11.044571,"eighty":-7.492045,"marketCap":940081543},{"date":"2025-08-01","current":-16.20487,"twenty":-16.158905,"median":-11.077981,"eighty":-7.667213,"marketCap":849102797},{"date":"2025-08-08","current":-17.484059,"twenty":-16.20487,"median":-11.141188,"eighty":-7.667213,"marketCap":916129723},{"date":"2025-08-15","current":-22.268769,"twenty":-16.33076,"median":-11.193196,"eighty":-7.674511,"marketCap":1166838947},{"date":"2025-08-22","current":-21.691773,"twenty":-16.434778,"median":-11.220775,"eighty":-7.693556,"marketCap":1136605525},{"date":"2025-08-29","current":-20.793619,"twenty":-16.611183,"median":-11.233899,"eighty":-7.743848,"marketCap":1089544067},{"date":"2025-09-05","current":-21.729877,"twenty":-16.749673,"median":-11.252126,"eighty":-7.89274,"marketCap":1138602072},{"date":"2025-09-12","current":-22.214335,"twenty":-16.928962,"median":-11.290275,"eighty":-7.953319,"marketCap":1163986737},{"date":"2025-09-19","current":-22.693351,"twenty":-17.073997,"median":-11.339198,"eighty":-7.982513,"marketCap":1189086182},{"date":"2025-09-26","current":-21.789753,"twenty":-17.210778,"median":-11.419321,"eighty":-7.998378,"marketCap":1141739502},{"date":"2025-10-03","current":-26.302295,"twenty":-17.347559,"median":-11.473592,"eighty":-8.003646,"marketCap":1378187678},{"date":"2025-10-10","current":-25.175521,"twenty":-17.497557,"median":-11.534645,"eighty":-8.0071,"marketCap":1319146940},{"date":"2025-10-17","current":-22.018374,"twenty":-17.690689,"median":-11.749464,"eighty":-8.107241,"marketCap":1153718783},{"date":"2025-10-24","current":-16.034033,"twenty":-17.707197,"median":-11.991418,"eighty":-8.145558,"marketCap":840151237},{"date":"2025-10-31","current":-15.563946,"twenty":-17.690689,"median":-12.292165,"eighty":-8.168128,"marketCap":815519652},{"date":"2025-11-07","current":-10.439663,"twenty":-17.665927,"median":-12.292165,"eighty":-8.196087,"marketCap":614718687},{"date":"2025-11-14","current":-14.07658,"twenty":-17.595178,"median":-12.325665,"eighty":-8.25011,"marketCap":828871278},{"date":"2025-11-21","current":-14.730193,"twenty":-17.553908,"median":-12.761733,"eighty":-8.286974,"marketCap":867357940},{"date":"2025-11-28","current":-16.218091,"twenty":-17.524554,"median":-12.861347,"eighty":-8.308212,"marketCap":954969853},{"date":"2025-12-05","current":-14.825843,"twenty":-17.466248,"median":-13.119398,"eighty":-8.337771,"marketCap":872990135},{"date":"2025-12-12","current":-13.01911,"twenty":-17.42774,"median":-13.221067,"eighty":-8.354198,"marketCap":766604240},{"date":"2025-12-19","current":-9.070865,"twenty":-17.407695,"median":-13.037789,"eighty":-8.414622,"marketCap":534119770},{"date":"2025-12-26","current":-9.108063,"twenty":-17.390007,"median":-12.866196,"eighty":-8.500376,"marketCap":536310068},{"date":"2026-01-02","current":-8.502276,"twenty":-17.333409,"median":-12.777948,"eighty":-8.502276,"marketCap":500639504},{"date":"2026-01-09","current":-8.098418,"twenty":-17.315721,"median":-12.328345,"eighty":-8.502276,"marketCap":476859127},{"date":"2026-01-16","current":-9.639455,"twenty":-17.280347,"median":-12.249123,"eighty":-8.498134,"marketCap":567600037},{"date":"2026-01-23","current":-11.302713,"twenty":-17.228465,"median":-12.093174,"eighty":-8.501448,"marketCap":665537640},{"date":"2026-01-30","current":-9.448154,"twenty":-17.210778,"median":-11.871572,"eighty":-8.502276,"marketCap":556335648},{"date":"2026-02-06","current":-7.42355,"twenty":-17.195449,"median":-11.633633,"eighty":-8.39709,"marketCap":437120866},{"date":"2026-02-13","current":-6.892157,"twenty":-17.156729,"median":-11.509772,"eighty":-8.290687,"marketCap":405830897},{"date":"2026-02-20","current":-6.403276,"twenty":-17.117721,"median":-11.432889,"eighty":-8.236123,"marketCap":377044126},{"date":"2026-02-27","current":-7.184423,"twenty":-17.08343,"median":-11.396709,"eighty":-8.118629,"marketCap":423040380},{"date":"2026-03-02","current":-7.168481,"twenty":-17.078714,"median":-11.387664,"eighty":-8.080293,"marketCap":422101681}],"updateTime":1772531073039},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LENZ\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2612448600","title":"Press Release: Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2612448600","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612448600?lang=en_us&edition=fundamental","pubTime":"2026-02-18 20:00","pubTimestamp":1771416000,"startTime":"0","endTime":"0","summary":"-- Board-certified allergist and leading food allergy and anaphylaxis. WARREN, N.J., Feb. 18, 2026  -- Aquestive Therapeutics, Inc.  , a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Matthew Greenhawt, MD, MBA, MSc, as Chief Medical Officer, strengthening its leadership team as the Company prepares to resubmit its Anaphylm New Drug Application  to the United Stated Food and Drug Administration  and advance its clinical pipeline.Dr. Greenhawt is an internationally recognized expert in allergy and immunology with particular expertise in food allergy, anaphylaxis, patient-centered care, and health services and health policy research. He brings extensive clinical, research, and advocacy experience to Aquestive at a critical juncture in the Company's history.\"Dr. Greenhawt's appointment represents another strong addition to the Aquestive leadership team,\" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4555","BK4604","BK4007","BK4022","AQST","BK4539","BK4588","CDMO","TM","R","BK4099","BK4232","LENZ","03160","BK4139"],"gpt_icon":0},{"id":"2612410937","title":"Galera Therapeutics Updates Preferred Stock Conversion Provisions","url":"https://stock-news.laohu8.com/highlight/detail?id=2612410937","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612410937?lang=en_us&edition=fundamental","pubTime":"2026-02-18 19:36","pubTimestamp":1771414607,"startTime":"0","endTime":"0","summary":"An announcement from Galera Therapeutics ( ($GRTX) ) is now available. On February 12, 2026, Galera Therapeutics, Inc. filed a Certificate of Amend...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/galera-therapeutics-updates-preferred-stock-conversion-provisions?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/galera-therapeutics-updates-preferred-stock-conversion-provisions?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4539","LENZ","BK4139"],"gpt_icon":0},{"id":"2612949958","title":"Atossa Therapeutics Regains Nasdaq Compliance, Avoids Delisting Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2612949958","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612949958?lang=en_us&edition=fundamental","pubTime":"2026-02-18 07:12","pubTimestamp":1771369933,"startTime":"0","endTime":"0","summary":"The latest update is out from Atossa Therapeutics ( ($ATOS) ). On February 17, 2026, Atossa Therapeutics, Inc. announced it had regained compliance...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/atossa-therapeutics-regains-nasdaq-compliance-avoids-delisting-risk?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/atossa-therapeutics-regains-nasdaq-compliance-avoids-delisting-risk?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","NQmain","LENZ","BK4007"],"gpt_icon":0},{"id":"2612349517","title":"Press Release: Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2612349517","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612349517?lang=en_us&edition=fundamental","pubTime":"2026-02-18 06:16","pubTimestamp":1771366560,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics Holdings Inc. , a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced that it will release its financial results for the quarter and year ended December 31, 2025 after the market close on Tuesday, March 3 and will also host a conference call and webcast at 4:30 p.m. Eastern Time on March 3, 2026.Arcturus Therapeutics Fourth Quarter and Fiscal Year 2025 Earnings Conference Call","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4505","BK4007","BK4232","LENZ","R","CF","IE0009354923.USD","BK4539","BK4585","RNA","BK4139","BK4093","ARCT","BK4588"],"gpt_icon":0},{"id":"2612464086","title":"Shield Therapeutics Iron Deficiency Drug Approved for Children","url":"https://stock-news.laohu8.com/highlight/detail?id=2612464086","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612464086?lang=en_us&edition=fundamental","pubTime":"2026-02-18 03:18","pubTimestamp":1771355880,"startTime":"0","endTime":"0","summary":"Shield Therapeutics' AccruFeR got additional approval from the Food and Drug Administration to treat iron deficiency.The prescription oral iron treatment was approved for children 10 and older, Shield said Tuesday, after receiving approval for adults in 2019.Iron deficiency affects about 2.4 million children in the U.S., with adolescents at particularly high risk, the London-based biopharmaceutical company said.AccruFeR is a novel, stable, non-salt-based oral therapy. It has a novel mechanism of absorption compared with other oral iron therapies and has been shown to be well-tolerated in clinical trials.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Shield Therapeutics Iron Deficiency Drug Approved for Children","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","BK4007","LENZ"],"gpt_icon":0},{"id":"2612274457","title":"Crispr Therapeutics price target raised to $33 from $32 at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2612274457","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612274457?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:36","pubTimestamp":1771335389,"startTime":"0","endTime":"0","summary":"Morgan Stanley raised the firm’s price target on Crispr Therapeutics (CRSP) to $33 from $32 and keeps an Underweight rating on the shares. The firm...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/crispr-therapeutics-price-target-raised-to-33-from-32-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/crispr-therapeutics-price-target-raised-to-33-from-32-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2612096452","title":"Outlook Therapeutics reports adjusted Q1 EPS (22c), consensus (17c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2612096452","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612096452?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:16","pubTimestamp":1771334200,"startTime":"0","endTime":"0","summary":"“Lytenava is demonstrating increasing adoption in Europe following our initial launches, with growing demand and quarter-over-quarter unit sales gr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/outlook-therapeutics-reports-adjusted-q1-eps-22c-consensus-17c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/outlook-therapeutics-reports-adjusted-q1-eps-22c-consensus-17c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2612945224","title":"Outlook Therapeutics Q1 Adj. EPS $(0.22) Misses $(0.18) Estimate, Sales $(1.208M) Miss $5.025M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2612945224","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612945224?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:10","pubTimestamp":1771333822,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics (NASDAQ:OTLK) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.18) by 22.22 percent. This is a 75.28 percent increase over losses of $(0.89) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50647489/outlook-therapeutics-q1-adj-eps-0-22-misses-0-18-estimate-sales-1-208m-miss-5-025m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"gpt_icon":0},{"id":"2612457526","title":"Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2612457526","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612457526?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:00","pubTimestamp":1771333200,"startTime":"0","endTime":"0","summary":"DOYLESTOWN, Pa., Feb.  17, 2026  (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies that","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/17/3239221/0/en/Aprea-Therapeutics-to-Present-at-Oppenheimer-36th-Annual-Healthcare-Life-Sciences-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","LU0128526141.USD","LENZ","BK4539","BK4137","BK4588","LABU","BK4007","BK4585","BK4139","BK4127","BK4581","OPY","HCSG","LU0029874061.USD","XBI"],"gpt_icon":0},{"id":"2612575144","title":"Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2612575144","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612575144?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:30","pubTimestamp":1771331400,"startTime":"0","endTime":"0","summary":"Fireside chat with management on February 25, 2026, at 9:20 a.m. ETNEW HAVEN, Conn., Feb.  17, 2026  (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/17/3239122/0/en/Trevi-Therapeutics-to-Participate-in-the-Oppenheimer-36th-Annual-Healthcare-Life-Sciences-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OPY","LU0128526141.USD","BK4127","BK4585","BK4581","BK4539","XLV","XBI","BK4139","BK4007","BK4588","HCSG","LABU","LU0029874061.USD","RCC","LENZ","BK4137"],"gpt_icon":0},{"id":"2612512254","title":"Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2612512254","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612512254?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:00","pubTimestamp":1771329600,"startTime":"0","endTime":"0","summary":"–Received Positive Pre-Investigational New Drug (“IND”) Written Feedback from the U.S. Food and Drug Administration (“FDA”)– –Clinical Advisory Board (“CAB”) Includes Key Leaders across Neuropsychiatr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/17/3239080/0/en/Cyclerion-Therapeutics-Announces-Progress-Toward-CYC-126-Phase-2-Proof-of-Concept-Study-with-FDA-Feedback-and-Formation-of-Clinical-Advisory-Board.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRGS","LENZ","LU2065732104.USD","BK4007","BK4139","BK4539","BK4097"],"gpt_icon":0},{"id":"2612459170","title":"Autolus Therapeutics Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2612459170","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612459170?lang=en_us&edition=fundamental","pubTime":"2026-02-17 19:46","pubTimestamp":1771328760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AUTL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 17, 2026 06:46 ET (11:46 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","AUTL","BK4139","BK4007","LENZ"],"gpt_icon":0},{"id":"2612456756","title":"Autolus Therapeutics initiated with a Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2612456756","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612456756?lang=en_us&edition=fundamental","pubTime":"2026-02-17 19:11","pubTimestamp":1771326676,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Emily Bodnar initiated coverage of Autolus Therapeutics (AUTL) with a Buy rating and $9 price target Th e firm says the com...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/autolus-therapeutics-initiated-with-a-buy-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/autolus-therapeutics-initiated-with-a-buy-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AUTL","BK4007","BK4539","LENZ","BK4139"],"gpt_icon":0},{"id":"2612552844","title":"Dianthus Therapeutics: Best-in-Class Complement Inhibitor Potential and Multiple 2026 Catalysts Support Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2612552844","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612552844?lang=en_us&edition=fundamental","pubTime":"2026-02-17 18:35","pubTimestamp":1771324526,"startTime":"0","endTime":"0","summary":"William Blair analyst Myles Minter has maintained their bullish stance on DNTH stock, giving a Buy rating on February 11. Myles Minter has given hi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/dianthus-therapeutics-best-in-class-complement-inhibitor-potential-and-multiple-2026-catalysts-support-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/dianthus-therapeutics-best-in-class-complement-inhibitor-potential-and-multiple-2026-catalysts-support-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2612310744","title":"Assessing CARsgen Therapeutics Holdings’ Valuation After New CAR T-Cell Manufacturing Cooperation News","url":"https://stock-news.laohu8.com/highlight/detail?id=2612310744","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612310744?lang=en_us&edition=fundamental","pubTime":"2026-02-17 10:18","pubTimestamp":1771294682,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics Holdings (SEHK:2171) has signed cooperation agreements via its subsidiary CARsgen Diagnostics with Shanghai Jingong Enterprise to build a commercial CAR T-cell manufacturing base in Shanghai, a move closely linked to its commercialization plans.\nSee our latest analysis for CARsgen Therapeutics Holdings.\nThe cooperation news comes as momentum in CARsgen Therapeutics Holdings' share price has recently picked up, with a 1-day share price return of 4.65% and a 7-day share...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2171/carsgen-therapeutics-holdings-shares/news/assessing-carsgen-therapeutics-holdings-valuation-after-new","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2171/carsgen-therapeutics-holdings-shares/news/assessing-carsgen-therapeutics-holdings-valuation-after-new","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LENZ","BK4539","BK1574","BK4230","CAR","BK1585","BK4022","BK4139","BK1587","BK4007","BK1161","02171"],"gpt_icon":0},{"id":"2611485986","title":"Crispr Therapeutics price target lowered to $67 from $69 at JPMorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2611485986","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611485986?lang=en_us&edition=fundamental","pubTime":"2026-02-16 21:00","pubTimestamp":1771246816,"startTime":"0","endTime":"0","summary":"JPMorgan lowered the firm’s price target on Crispr Therapeutics (CRSP) to $67 from $69 and keeps an Overweight rating on the shares. The company’s ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/crispr-therapeutics-price-target-lowered-to-67-from-69-at-jpmorgan-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/crispr-therapeutics-price-target-lowered-to-67-from-69-at-jpmorgan-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2611010583","title":"Dianthus Therapeutics: Multi-Indication Potential for Claseprubart Underpins Buy Rating Ahead of Key Phase II Readouts","url":"https://stock-news.laohu8.com/highlight/detail?id=2611010583","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611010583?lang=en_us&edition=fundamental","pubTime":"2026-02-16 13:05","pubTimestamp":1771218321,"startTime":"0","endTime":"0","summary":"William Blair analyst Myles Minter has maintained their bullish stance on DNTH stock, giving a Buy rating on February 11. Myles Minter has given hi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/dianthus-therapeutics-multi-indication-potential-for-claseprubart-underpins-buy-rating-ahead-of-key-phase-ii-readouts-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/dianthus-therapeutics-multi-indication-potential-for-claseprubart-underpins-buy-rating-ahead-of-key-phase-ii-readouts-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2611114725","title":"Crispr Therapeutics price target raised to $76 from $74 at Chardan","url":"https://stock-news.laohu8.com/highlight/detail?id=2611114725","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611114725?lang=en_us&edition=fundamental","pubTime":"2026-02-14 19:45","pubTimestamp":1771069513,"startTime":"0","endTime":"0","summary":"Chardan analyst Geulah Livshits raised the firm’s price target on Crispr Therapeutics (CRSP) to $76 from $74 and keeps a Buy rating on the shares f...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/crispr-therapeutics-price-target-raised-to-76-from-74-at-chardan-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/crispr-therapeutics-price-target-raised-to-76-from-74-at-chardan-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2611115353","title":"High-Risk Warning: Analyst Flags Significant Uncertainties for Vistagen Therapeutics Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2611115353","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611115353?lang=en_us&edition=fundamental","pubTime":"2026-02-14 14:01","pubTimestamp":1771048900,"startTime":"0","endTime":"0","summary":"Vistagen Therapeutics Inc. (VTGN) has disclosed a new risk, in the Accounting & Financial Operations category. The analyst notes that investing in ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/high-risk-warning-analyst-flags-significant-uncertainties-for-vistagen-therapeutics-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/high-risk-warning-analyst-flags-significant-uncertainties-for-vistagen-therapeutics-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ISBC","VTGN","BK4007","BK4539","LENZ","BK4211","BK4139"],"gpt_icon":0},{"id":"2611912221","title":"Vistagen Therapeutics Balances Progress and Uncertainty","url":"https://stock-news.laohu8.com/highlight/detail?id=2611912221","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611912221?lang=en_us&edition=fundamental","pubTime":"2026-02-14 08:13","pubTimestamp":1771027983,"startTime":"0","endTime":"0","summary":"Vistagen Therapeutics Inc. (($VTGN)) has held its Q3 earnings call. Read on for the main highlights of the call. Vistagen Therapeutics’ latest earn...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vistagen-therapeutics-balances-progress-and-uncertainty?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vistagen-therapeutics-balances-progress-and-uncertainty?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","PRGS","BK4539","BK4097","BK4139","LU2065732104.USD","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":200,"code":"91000000","status":"200"}]}}